Swedish Orphan Biovitrum AB (Sobi) announces the launch of an enhanced corporate sustainability programme with a strong connection to the company’s strategy of providing sustainable access to treatments for rare diseases.
As part of the new sustainability strategy, Sobi has identified several focus areas that are important for both the stakeholder communities and Sobi’s business. Sobi’s stakeholders include the communities of patients and caregivers affected by rare diseases, the local communities around the globe in which Sobi operates, the community of companies that form the biopharmaceutical industry, shareholders and the communities of individual employees who comprise Sobi.
“Sobi has a vision of becoming a global leader in providing access to innovative treatments that make a significant difference for individuals with rare diseases,” said Guido Oelkers, Sobi CEO. “Sustainability is a vital part of our vision and overall corporate strategy. A sustainable business entails a commitment to responsibility for patients and employees, reduced environmental impact from operations and treatment, as well as long-term sustainable profitability so that we can continue to reinvest in developing new therapies for rare diseases and serve our communities for many years to come.”
(Source: Sobi)
